Brucella β 1,2 Cyclic Glucan Is an Activator of Human and Mouse Dendritic Cells

PLoS Pathogens

Volumn 8, Issue 11, 2012, Pages

  Martirosyan, Anna ^a,b   Pérez Gutierrez, Camino ^c   Banchereau, Romain ^d   Dutartre, Hélène ^d   Lecine, Patrick ^d   Dullaers, Melissa ^e   Mello, Marielle ^a,b   Pinto Salcedo, Suzana ^a,b   Muller, Alexandre ^a,b   Leserman, Lee ^a,b   Levy, Yves ^f,g,h   Zurawski, Gerard ^d   Zurawski, Sandy ^d   Moreno, Edgardo ^i,j   Moriyón, Ignacio ^k   Klechevsky, Eynav ^d,l   Banchereau, Jacques ^d,m   Oh, SangKon ^d   Gorvel, Jean Pierre ^a,b  

^a CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^b INSERM   (France)

^c Laboratory Microbial Patogénesis   (Spain)

^d BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^e Laboratory of Immunoregulation and Mucosal Immunity   (Belgium)

^f INSERM U955   (France)

^g FACULTÉ DE MÉDECINE   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ UNIVERSIDAD NACIONAL   (Costa Rica)

^j UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^k UNIVERSITY OF NAVARRA   (Spain)

^l WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m Pharma Research and Early Development   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; BETA 1, 2 CYCLIC GLUCAN; BREFELDIN A; CD40 LIGAND; CD86 ANTIGEN; GAMMA INTERFERON; GLUCAN; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; IONOMYCIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELOID DIFFERENTIATION FACTOR 88; PATTERN RECOGNITION RECEPTOR; PHOSPHORYL LIPID A; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANIMLA EXPERIMENT; ARTICLE; BRUCELLA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD14; BRUCELLA; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DENDRITIC CELLS; GLUCANS; HUMANS; MICE; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; TOLL-LIKE RECEPTOR 4;

ALPHAPROTEOBACTERIA; BACTERIA (MICROORGANISMS); BRUCELLA; HEPATITIS C VIRUS; MYCOBACTERIUM TUBERCULOSIS; NEGIBACTERIA;

EID: 84870795497     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002983     Document Type: Article

References (47)

1. Breedveld MW, Miller KJ, (1994) Cyclic beta-glucans of members of the family Rhizobiaceae. Microbiol Rev 58: 145-161.
2. Martirosyan A, Moreno E, Gorvel JP, (2011) An evolutionary strategy for a stealthy intracellular Brucella pathogen. Immunol Rev 240: 211-234.
3. Gorvel JP, Moreno E, (2002) Brucella intracellular life: from invasion to intracellular replication. Vet Microbiol 90: 281-297.
4. Inon de Iannino N, Briones G, Tolmasky M, Ugalde RA, (1998) Molecular cloning and characterization of cgs, the Brucella abortus cyclic beta(1-2) glucan synthetase gene: genetic complementation of Rhizobium meliloti ndvB and Agrobacterium tumefaciens chvB mutants. J Bacteriol 180: 4392-4400.
5. Briones G, Inon de Iannino N, Roset M, Vigliocco A, Paulo PS, et al. (2001) Brucella abortus cyclic beta-1,2-glucan mutants have reduced virulence in mice and are defective in intracellular replication in HeLa cells. Infect Immun 69: 4528-4535.
6. Arellano-Reynoso B, Lapaque N, Salcedo S, Briones G, Ciocchini AE, et al. (2005) Cyclic beta-1,2-glucan is a Brucella virulence factor required for intracellular survival. Nat Immunol 6: 618-625.
7. Hong F, Hansen RD, Yan J, Allendorf DJ, Baran JT, et al. (2003) Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res 63: 9023-9031.
8. Ross GD, Vetvicka V, Yan J, Xia Y, Vetvickova J, (1999) Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology 42: 61-74.
9. Li J, Li DF, Xing JJ, Cheng ZB, Lai CH, (2006) Effects of beta-glucan extracted from Saccharomyces cerevisiae on growth performance, and immunological and somatotropic responses of pigs challenged with Escherichia coli lipopolysaccharide. J Anim Sci 84: 2374-2381.
10. Hetland G, Ohno N, Aaberge IS, Lovik M, (2000) Protective effect of beta-glucan against systemic Streptococcus pneumoniae infection in mice. FEMS Immunol Med Microbiol 27: 111-116.
11. Hetland G, Lovik M, Wiker HG, (1998) Protective effect of beta-glucan against mycobacterium bovis, BCG infection in BALB/c mice. Scand J Immunol 47: 548-553.
12. Liang J, Melican D, Cafro L, Palace G, Fisette L, et al. (1998) Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int J Immunopharmacol 20: 595-614.
13. Brown GD, Gordon S, (2005) Immune recognition of fungal beta-glucans. Cell Microbiol 7: 471-479.
14. Goodridge HS, Wolf AJ, Underhill DM, (2009) Beta-glucan recognition by the innate immune system. Immunol Rev 230: 38-50.
15. Lambrecht BN, Kool M, Willart MA, Hammad H, (2009) Mechanism of action of clinically approved adjuvants. Current opinion in immunology 21: 23-29.
16. Petrovsky N, Aguilar JC, (2004) Vaccine adjuvants: current state and future trends. Immunology and cell biology 82: 488-496.
17. Lahiri A, Das P, Chakravortty D, (2008) Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 26: 6777-6783.
18. De Gregorio E, D'Oro U, Wack A, (2009) Immunology of TLR-independent vaccine adjuvants. Curr Opin Immunol 21: 339-345.
19. Salcedo SP, Marchesini MI, Lelouard H, Fugier E, Jolly G, et al. (2008) Brucella control of dendritic cell maturation is dependent on the TIR-containing protein Btp1. PLoS Pathog 4: e21.
20. Bohin JP, (2000) Osmoregulated periplasmic glucans in Proteobacteria. FEMS Microbiol Lett 186: 11-19.
21. Roset MS, Ciocchini AE, Ugalde RA, Inon de Iannino N, (2006) The Brucella abortus cyclic beta-1,2-glucan virulence factor is substituted with O-ester-linked succinyl residues. J Bacteriol 188: 5003-5013.
22. Palma AS, Feizi T, Zhang Y, Stoll MS, Lawson AM, et al. (2006) Ligands for the beta-glucan receptor, Dectin-1, assigned using "designer" microarrays of oligosaccharide probes (neoglycolipids) generated from glucan polysaccharides. J Biol Chem 281: 5771-5779.
23. Gross O, Gewies A, Finger K, Schafer M, Sparwasser T, et al. (2006) Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 442: 651-656.
24. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, et al. (2004) Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 34: 796-805.
25. Dai J, Megjugorac NJ, Amrute SB, Fitzgerald-Bocarsly P, (2004) Regulation of IFN regulatory factor-7 and IFN-alpha production by enveloped virus and lipopolysaccharide in human plasmacytoid dendritic cells. J Immunol 173: 1535-1548.
26. Sekar D, Brune B, Weigert A, (2010) Technical advance: Generation of human pDC equivalents from primary monocytes using Flt3-L and their functional validation under hypoxia. J Leukoc Biol 88: 413-424.
27. Miller SI, Ernst RK, Bader MW, (2005) LPS, TLR4 and infectious disease diversity. Nature Rev Microbiol 3: 36-46.
28. Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, et al. (2008) Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 29: 497-510.
29. Klechevsky E, Flamar AL, Cao Y, Blanck JP, Liu M, et al. (2010) Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 116: 1685-1697.
30. Ueno H, Klechevsky E, Schmitt N, Ni L, Flamar AL, et al. (2011) Targeting human dendritic cell subsets for improved vaccines. Seminars in immunology 23: 21-27.
31. Pulendran B, Ahmed R, (2011) Immunological mechanisms of vaccination. Nature Immunol 12: 509-517.
32. Mellman I, Steinman RM, (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106: 255-258.
33. Kapsenberg ML, (2003) Dendritic-cell control of pathogen-driven T-cell polarization. Nature Rev Immunol 3: 984-993.
34. Romero CD, Varma TK, Hobbs JB, Reyes A, Driver B, et al. (2011) The Toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection. Infect Immun 79: 3576-3587.
35. Khatri I, Alexander C, Brandenburg K, Fournier K, Mach JP, et al. (2009) Induction of tolerogenic vs immunogenic dendritic cells (DCs) in the presence of GM-CSF is regulated by the strength of signaling from monophosphoryl lipid A (MPLA) in association with glutathione and fetal hemoglobin gamma-chain. Immunol Lett 124: 44-49.
36. Desvignes L, Wolf AJ, Ernst JD, (2012) Dynamic Roles of Type I and Type II IFNs in Early Infection with Mycobacterium tuberculosis. J Immunol 188: 6205-15.
37. Yuan TM, Sun Y, Zhan CY, Yu HM, (2010) Intrauterine infection/inflammation and perinatal brain damage: role of glial cells and Toll-like receptor signaling. J Neuroimmunol 229: 16-25.
38. Szabo G, Dolganiuc A, Dai Q, Pruett SB, (2007) TLR4, ethanol, and lipid rafts: a new mechanism of ethanol action with implications for other receptor-mediated effects. J Immunol 178: 1243-1249.
39. Legat A, Thomas S, Hermand P, Van Mechelen M, Goldman M, et al. (2010) CD14-independent responses induced by a synthetic lipid A mimetic. Eur J Immunol 40: 797-802.
40. Sirard JC, Bayardo M, Didierlaurent A, (2006) Pathogen-specific TLR signaling in mucosa: mutual contribution of microbial TLR agonists and virulence factors. Eur J Immunol 36: 260-263.
41. Lelouard H, Gatti E, Cappello F, Gresser O, Camosseto V, et al. (2002) Transient aggregation of ubiquitinated proteins during dendritic cell maturation. Nature 417: 177-182.
42. Aragon V, Diaz R, Moreno E, Moriyon I, (1996) Characterization of Brucella abortus and Brucella melitensis native haptens as outer membrane O-type polysaccharides independent from the smooth lipopolysaccharide. J Bacteriol 178: 1070-1079.
43. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, et al. (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176: 1693-1702.
44. Dhodapkar KM, Kaufman JL, Ehlers M, Banerjee DK, Bonvini E, et al. (2005) Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci U S A 102: 2910-2915.
45. Ciocchini AE, Guidolin LS, Casabuono AC, Couto AS, de Iannino NI, et al. (2007) A glycosyltransferase with a length-controlling activity as a mechanism to regulate the size of polysaccharides. Proc Natl Acad Sci U S A 104: 16492-16497.
46. Conde-Álvarez R, Arce-Gorvel V, Iriarte M, Manček-Keber M, Barquero-Calvo E, et al. (2012) The Lipopolysaccharide Core of Brucella abortus Acts as a Shield Against Innate Immunity Recognition. PLoS Pathog 8: e1002675.
47. Moreno E, Speth SL, Jones LM, Berman DT, (1981) Immunochemical characterization of Brucella lipopolysaccharides and polysaccharides. Infect Immun 31: 214-222.